Patents by Inventor Angelos CONSTANTINOU

Angelos CONSTANTINOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma
    Patent number: 10676791
    Abstract: The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSR v) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSg o
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: June 9, 2020
    Assignees: INSERM(INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Jerome Moreaux, Guillaume Cartron, Caroline Bret, Angelos Constantinou, Philippe Pasero
  • METHODS FOR PREDICTING RESPONSE TO DNA REPAIR PATHWAY INHIBITORS IN DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20170211151
    Abstract: The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSR v) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSg o
    Type: Application
    Filed: July 27, 2015
    Publication date: July 27, 2017
    Inventors: Jérôme MOREAUX, Guillaume CARTRON, Caroline BRET, Angelos CONSTANTINOU, Philippe PASERO